"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
Malave L, Zuelke DR, Uribe-Cano S, Starikov L, Rebholz H, Friedman E, Qin C, Li Q, Bezard E, Kottmann AH. Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia. Commun Biol. 2021 09 22; 4(1):1071.
-
Castello J, Cort?s M, Malave L, Kottmann A, Sibley DR, Friedman E, Rebholz H. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Sci Rep. 2020 02 13; 10(1):2542.
-
Camacho E, Vij R, Chrissian C, Prados-Rosales R, Gil D, O'Meally RN, Cordero RJB, Cole RN, McCaffery JM, Stark RE, Casadevall A. The structural unit of melanin in the cell wall of the fungal pathogen Cryptococcus neoformans. J Biol Chem. 2019 07 05; 294(27):10471-10489.
-
Chatterjee S, Prados-Rosales R, Tan S, Phan VC, Chrissian C, Itin B, Wang H, Khajo A, Magliozzo RS, Casadevall A, Stark RE. The melanization road more traveled by: Precursor substrate effects on melanin synthesis in cell-free and fungal cell systems. J Biol Chem. 2018 12 28; 293(52):20157-20168.
-
Chatterjee S, Prados-Rosales R, Itin B, Casadevall A, Stark RE. Solid-state NMR Reveals the Carbon-based Molecular Architecture of Cryptococcus neoformans Fungal Eumelanins in the Cell Wall. J Biol Chem. 2015 May 29; 290(22):13779-90.
-
Smith ML, King J, Dent L, Mackey V, Muthian G, Griffin B, Charlton CG. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease. Life Sci. 2014 Aug 06; 110(1):1-7.
-
Tse GG, Kim BB, McMurtray AM, Nakamoto BK. Case of levodopa toxicity from ingestion of Mucuna gigantea. Hawaii J Med Public Health. 2013 May; 72(5):157-60.
-
Wang Z, Ferdousy F, Lawal H, Huang Z, Daigle JG, Izevbaye I, Doherty O, Thomas J, Stathakis DG, O'Donnell JM. Catecholamines up integrates dopamine synthesis and synaptic trafficking. J Neurochem. 2011 Dec; 119(6):1294-305.
-
King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011 Oct 24; 89(17-18):638-43.
-
Ferguson MC, Nayyar T, Deutch AY, Ansah TA. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2010 Jul-Aug; 59(1-2):31-6.